Groundbreaking Medical Cannabis Study and the Opioid Crisis
The escalating crisis of opioid overuse and dependency has plagued the nation for years. Yet, there emerges a gleam of hope from New York. A groundbreaking study, recently published in the Journal of the American Medical Association Network Open, suggests that medical cannabis might be the missing link in the fight against opioid dependence.
The results of the peer-reviewed study, Changes in Prescribed Opioid Dosages Among Patients Receiving Medical Cannabis for Chronic Pain, New York State, 2017-2019, in combination with existing evidence, show that managing chronic pain with medical cannabis may reduce the opioid burden. This may, in turn, reduce the risk of illicit use and overdose for patients on long-term opioid therapy.
Changes in Prescribed Opioid Dosages Among Patients Receiving Medical Cannabis for Chronic Pain
Conducted over two years, this multi-agency study illuminated the remarkable connection between medical cannabis use for chronic pain and a decrease in prescription opioid dosage.
Astonishingly, the patients on higher baseline opioid dosages witnessed a staggering reduction of up to 51% in their prescription dosages after integrating medical cannabis into their treatment for just eight months.
In contrast, shorter-term use of medical cannabis yielded only a 4% to 14% decrease.
Dramatics Shift in Potential Treatments for Chronic Pain
These findings aren’t mere statistics; they signify a dramatic shift in the way we perceive and manage chronic pain.
Dr. Danielle Greene of CUNY emphasizes the societal impact, suggesting a "more humane option for achieving lower prescription dosages," thereby reducing the risks associated with abrupt withdrawal from high-dosage opioids. The ripple effect of such reductions could be monumental, potentially curtailing the use of illicit drugs, overdose incidents, and self-harm.
Furthermore, while many New Yorkers had shared anecdotal evidence about the potential of medical cannabis in managing pain, this study provides concrete, peer-reviewed evidence.
As Nicole Quackenbush of the NYS Office of Cannabis Management notes, the research sheds light on "a statistically and clinically significant reduction" in opioid dosages for patients who've been on medical cannabis longer.
Medical Cannabis Could Reshape Pain Management
The implications of this research go far beyond New York. It acts as a beacon for other jurisdictions, particularly where medical cannabis remains underutilized or illegal. By showcasing tangible benefits, it beckons policymakers and healthcare providers to rethink and reshape the future of pain management.
Join OMNI Medical Cannabis Doctors Research Group Today
As we forge ahead in our relentless pursuit of better health outcomes, this study serves as a timely reminder: nature might just have the solutions we've been seeking all along. With continued research and an open mind, a brighter, less opioid-dependent future could be on the horizon.
Want to join in Medical Cannabis Research?
Now you can with OMNI Medical Cannabis Research Group. Join today!